COLOMBO NICOLETTA

Tewari, K., Colombo, N., Monk, B., Dubot, C., Caceres, M., Hasegawa, K., et al. (2024). Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. JAMA ONCOLOGY, 10(2), 185-192 [10.1001/jamaoncol.2023.5410]. Detail

Caldarelli, M., Rezzi, S., Colombo, N., Pirali, T., Papeo, G. (2024). Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins. JOURNAL OF ORGANIC CHEMISTRY, 89(1), 633-643 [10.1021/acs.joc.3c02386]. Detail

Oaknin, A., Gladieff, L., Martínez-García, J., Villacampa, G., Takekuma, M., De Giorgi, U., et al. (2024). Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. THE LANCET, 403(10421 (6–12 January 2024)), 31-43 [10.1016/S0140-6736(23)02405-4]. Detail

Monk, B., Colombo, N., Tewari, K., Tekin, C., Keefe, S., Lorusso, D. (2024). Reply to P.-H. Luo et al. JOURNAL OF CLINICAL ONCOLOGY [10.1200/JCO.24.00077]. Detail

Betella, I., De Vitis, L., Calidona, C., Multinu, F., Colombo, N. (2024). Letter to the editor-The new FIGO staging system for endometrial cancer: Is the paradigm shift clinically feasible?. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 164(1), 364-365 [10.1002/ijgo.15265]. Detail